News and Events

News

All categories

Earnings

Press Release

All years

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022

May 24, 2022

Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity

May 16, 2022

Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

May 12, 2022

Affimed Provides Update on ASCO AFM13-104 Oral Presentation

May 6, 2022

Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

April 27, 2022

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 18, 2022

Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares

April 13, 2022

Affimed Announces Proposed Public Offering of Common Shares

April 12, 2022

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

April 10, 2022

Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors

April 8, 2022

Events

All

Scientific

Investors

18Oct

Innate Killer Summit Europe

October 18 - 20, 2022 (London, UK)

02Nov

Onco Cell Therapy Summit

November 2 - 3, 2022 (Amsterdam, NL)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022

Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity

Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Affimed Provides Update on ASCO AFM13-104 Oral Presentation

Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares

Affimed Announces Proposed Public Offering of Common Shares

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors

Events

Innate Killer Summit Europe

Onco Cell Therapy Summit